[go: up one dir, main page]

BRPI0512526A - composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida) - Google Patents

composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)

Info

Publication number
BRPI0512526A
BRPI0512526A BRPI0512526-0A BRPI0512526A BRPI0512526A BR PI0512526 A BRPI0512526 A BR PI0512526A BR PI0512526 A BRPI0512526 A BR PI0512526A BR PI0512526 A BRPI0512526 A BR PI0512526A
Authority
BR
Brazil
Prior art keywords
bis
salt
treating
cancer patient
thiohydrazide amide
Prior art date
Application number
BRPI0512526-0A
Other languages
English (en)
Inventor
Elena Kostik
Farid Vaghefi
Keizo Koya
Noriaki Tatsuta
Takayo Inoue
Guiqing Liang
Lijun Sun
Shoujun Chen
Zhi-Qiang Xia
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of BRPI0512526A publication Critical patent/BRPI0512526A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR UM PACIENTE COM CáNCER E MéTODO PARA PREPARAR UM DI-SAL DE BIS (TIO-HIDRAZIDA AMIDA) Trata-se de di-sais de bis(tio-hidrazida amida), que são representados pela Fórmula Estrutural (I), Y é uma ligação covalente ou um grupo hidrocarbila de cadeia linear, substituído ou não substituído. R~1~-R~4~ são independentemente -H, um grupo alifático, um grupo alifático substituído, um grupo arila ou um grupo arila substituído, ou R~1~ e R~3~ tomados juntos com o carbono e átomos de nitrogênio aos quais eles estão ligados, e/ou R~2~ e R~4~ tomados juntos com o carbono e átomos de nitrogênio aos quais eles estão ligados, formam um anel heterocíclico não aromático opcionalmente fundido a um anel aromático. Z é -O ou -S. M+ é um cátion monovalente farmaceuticamente aceitável e M²+ é um cátion divalente farmaceuticamente aceitável. São também descritas composições farmacêuticas que compreendem um di-sal de bis(tio-hidrazida amida) descrito acima. Ainda revelados são métodos para o tratamento de um paciente com câncer. Os métodos compreendem a etapa de administrar urna quantidade eficaz de um di-sal de bis(tio-hidrazida amida) descrito acima.
BRPI0512526-0A 2004-06-23 2005-06-20 composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida) BRPI0512526A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58259604P 2004-06-23 2004-06-23
US68136805P 2005-05-16 2005-05-16
PCT/US2005/021642 WO2006009940A1 (en) 2004-06-23 2005-06-20 Bis(thio-hydrazide amide) salts for treatment of cancers

Publications (1)

Publication Number Publication Date
BRPI0512526A true BRPI0512526A (pt) 2008-03-11

Family

ID=34993190

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512526-0A BRPI0512526A (pt) 2004-06-23 2005-06-20 composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)

Country Status (22)

Country Link
US (5) US7385084B2 (pt)
EP (2) EP1781604B1 (pt)
JP (1) JP5362986B2 (pt)
KR (1) KR101313027B1 (pt)
CN (1) CN1993318B (pt)
AU (1) AU2005265202B2 (pt)
BR (1) BRPI0512526A (pt)
CA (1) CA2570698C (pt)
DK (1) DK1781604T3 (pt)
ES (1) ES2430373T3 (pt)
HK (1) HK1104526A1 (pt)
HR (1) HRP20131023T1 (pt)
IL (1) IL179632A (pt)
ME (1) ME01644B (pt)
NO (1) NO20070378L (pt)
NZ (1) NZ552159A (pt)
PL (1) PL1781604T3 (pt)
PT (1) PT1781604E (pt)
RS (1) RS52999B (pt)
RU (2) RU2406722C2 (pt)
TW (1) TWI389684B (pt)
WO (1) WO2006009940A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
WO2006009940A1 (en) 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
AU2006236534A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
MX2007014314A (es) * 2005-05-16 2008-02-11 Synta Pharmaceuticals Corp Sintesis de sales de bis(tio-hidrazida amida).
AU2006279891B2 (en) * 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
US20100310587A1 (en) * 2005-08-29 2010-12-09 Academia Sinica Immunomodulatory compositions
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8609720B2 (en) 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8785451B2 (en) 2006-08-21 2014-07-22 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
WO2008024305A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
US20100068174A1 (en) * 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
EP2076254A2 (en) * 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
WO2009064374A2 (en) * 2007-11-09 2009-05-22 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8633323B2 (en) * 2008-03-31 2014-01-21 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
US9174935B2 (en) 2008-10-22 2015-11-03 Synta Pharmaceuticals Corp. Transition metal complexes of bis[thiohydrazide amide] compounds
CN102256949B (zh) 2008-10-22 2014-09-24 辛塔医药品有限公司 双[硫代酰肼酰胺]化合物的过渡金属络合物
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
AU2009322603B2 (en) 2008-12-01 2013-08-29 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8822532B2 (en) 2009-12-04 2014-09-02 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
US8815945B2 (en) 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
WO2012068491A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
AU2012335105A1 (en) * 2011-11-10 2014-06-19 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
US20150057357A1 (en) * 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (pt) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
PT693924E (pt) * 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
BR9507914A (pt) 1994-06-03 1997-09-23 Basf Ag Carbamoil-carbo hidrazida processo para preparar carbamoil-carbo-hidrazida composição adequada e processo para controlar fungos nocivos uso da carbamoil-carbo-hidrazida e amino-ácido-hidrazida
WO1997011094A1 (en) 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2191015C2 (ru) * 1999-11-05 2002-10-20 Общество с ограниченной ответственностью "Центр бифункциональных иммуномодуляторов" Динатриевая соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'- изоникотиноилгидразида, проявляющая антимикробную и иммунотропную активность, и лекарственное средство на ее основе
US6322303B1 (en) 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
EP1360173A2 (en) 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20020198160A1 (en) * 2001-05-01 2002-12-26 Everitt Elizabeth A. Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US20050154039A1 (en) * 2001-11-28 2005-07-14 Marie-Odile Glacera Contour 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
BRPI0407403B1 (pt) 2003-02-11 2022-07-19 Cancer Research Technology Ltd Compostos de isoxazol e composição farmacêutica
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
KR100486693B1 (ko) * 2003-03-17 2005-05-03 삼성전자주식회사 금속 매립 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
CA2560954A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
US7011923B2 (en) * 2004-04-07 2006-03-14 International Business Machines Corporation Negative photoresist and method of using thereof
WO2006009940A1 (en) * 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
WO2006062732A2 (en) 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
AU2006236534A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
MX2007014314A (es) 2005-05-16 2008-02-11 Synta Pharmaceuticals Corp Sintesis de sales de bis(tio-hidrazida amida).
AU2006279891B2 (en) 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US8609720B2 (en) 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008024305A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
US20080176828A1 (en) 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
US20100068174A1 (en) 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
CA2661440A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2076254A2 (en) 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
WO2008033300A2 (en) 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
EP2059250A2 (en) 2006-09-14 2009-05-20 Synta Pharmaceuticals Corporation Compounds for the treatment of angiogenesis
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TW200922550A (en) 2007-08-07 2009-06-01 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
WO2009064374A2 (en) 2007-11-09 2009-05-22 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009073148A2 (en) 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
JP5091056B2 (ja) 2008-08-28 2012-12-05 三甲株式会社 密閉容器の蓋部シール構造

Also Published As

Publication number Publication date
RU2010145056A (ru) 2012-05-20
IL179632A0 (en) 2007-05-15
TWI389684B (zh) 2013-03-21
US8461208B2 (en) 2013-06-11
CN1993318B (zh) 2012-10-03
TW200612895A (en) 2006-05-01
CA2570698A1 (en) 2006-01-26
WO2006009940A1 (en) 2006-01-26
RU2007101898A (ru) 2008-07-27
PL1781604T3 (pl) 2014-01-31
RU2406722C2 (ru) 2010-12-20
US20090281172A1 (en) 2009-11-12
EP1781604A1 (en) 2007-05-09
CN1993318A (zh) 2007-07-04
US20060135595A1 (en) 2006-06-22
RS52999B (en) 2014-02-28
HRP20131023T1 (hr) 2013-12-06
US7385084B2 (en) 2008-06-10
US20080269340A1 (en) 2008-10-30
US8048925B2 (en) 2011-11-01
KR20070029259A (ko) 2007-03-13
ME01644B (me) 2014-09-20
KR101313027B1 (ko) 2013-10-02
US7579503B2 (en) 2009-08-25
JP5362986B2 (ja) 2013-12-11
AU2005265202A1 (en) 2006-01-26
CA2570698C (en) 2013-11-19
US20120035266A1 (en) 2012-02-09
PT1781604E (pt) 2013-10-15
AU2005265202B2 (en) 2009-07-23
HK1104526A1 (en) 2008-01-18
NO20070378L (no) 2007-03-16
EP1781604B1 (en) 2013-08-07
NZ552159A (en) 2009-12-24
JP2008504264A (ja) 2008-02-14
IL179632A (en) 2012-08-30
US20100324143A1 (en) 2010-12-23
US7795313B2 (en) 2010-09-14
EP2305642A2 (en) 2011-04-06
EP2305642A3 (en) 2011-12-14
DK1781604T3 (da) 2013-09-16
ES2430373T3 (es) 2013-11-20

Similar Documents

Publication Publication Date Title
BRPI0512526A (pt) composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
BR0211227A (pt) Composto, composição farmacêutica e seus usos
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
AR055916A1 (es) Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BRPI0519058A2 (pt) composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
AR015312A1 (es) Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos
WO2006055747A3 (en) Bis(thio-hydrazide amides) for increasing hsp70 expression
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
ATE94061T1 (de) Arylsubstituierte aminderivate verwendbar in der krebstherapie.
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
BR0007784A (pt) Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
GB1425846A (en) 2-phenylamino-imidazolines-2- and the acid addition salts thereof processes for their preparation and pharmaceutical compositions containing the same
AR021826A1 (es) COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]